Aerie Pharmaceuticals Looks to Raise $57.5M for Glaucoma Drug Through IPO

Bedminster, N.J.-based Aerie Pharmaceuticals is looking to raise $57.5 million from an initial public offering, according to an Xconomy report.

Advertisement
Heather Linder

Aerie plans to use the money for supporting and promoting its glaucoma drug candidate through clinical trials. The company has raised $63.5 million from investors since it was founded in 2005.

More Articles on Ophthalmology:
5 Ways Healthcare Reform Will Impact Ophthalmologists
Ophthalmic Laser Company Lumenis Receives FDA 510(k) Approval
Ophthalmologist Dr. Benjamin Hale Joins Geisinger Health System in Pennsylvania

How the University of South Florida’s EP cardiac clinic drove 67% patient growth + doubled cardiac monitoring revenue

Recommended Whitepaper

Advertisement

Next Up in Ophthalmology

  • Montana physician practice acquired 

    Southlake, Texas-based Retina Consultants of America has acquired Montana Retina Consultants, according to a Feb. 5 news release.  Bozeman-based Montana…

    By: Patsy Newitt

  • Louisiana ophthalmology practice acquired 

    Vision Innovation Partners acquired Ophthalmic Associates of Alexandria (Va.), according to a Feb. 2 press release. Founded in 2010, Ophthalmic…

    By: Patsy Newitt
Advertisement

Comments are closed.